With the advent of molecular testing for MSI, RAS (KRAS, NRAS) and BRAF mutations, accurate and tailored treatment for advanced CRC is possible.21 These tumor genetic insights have shed light on their precursor lesions as well. Here, KRAS is linked to neoplasm.